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Phenotypic heterogeneity has been widely observed in cellular populations. However, the extent to
which heterogeneity contains biologically or clinically important information is not well under-
stood. Here, we investigated whether patterns of basal signaling heterogeneity, in untreated cancer
cell populations, could distinguish cellular populations with different drug sensitivities. We
modeled cellular heterogeneity as a mixture of stereotyped signaling states, identiﬁed based on
colocalization patterns of activated signaling molecules from microscopy images. We found that
patterns of heterogeneity could be used to separate the most sensitive and resistant populations to
paclitaxel within a set of H460 lung cancer clones and within the NCI-60 panel of cancer cell lines,
but not for a set of less heterogeneous, immortalized noncancer human bronchial epithelial cell
(HBEC) clones. Our results suggest that patterns of signaling heterogeneity, characterized as
ensembles of a small number of distinct phenotypic states, can reveal functional differences among
cellular populations.
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Introduction
Phenotypic heterogeneity is a commonly observed phenom-
enon in biology (Elsasser, 1984; Rubin, 1990). The physiolo-
gical importance of phenotypic heterogeneity within cellular
populations has been poorly understood. However, a growing
body of evidence suggests that heterogeneity—even within
clonal populations—may have functional consequences, such
as effects on survival odds or homeostatic responses in
response to ﬂuctuating environments, pathogen invasion, or
drug treatment (Luria and Delbruck,1943; Balaban et al, 2004;
Anderson etal,2006;Suelet al,2007; Chang etal, 2008; Cohen
et al, 2008; Feinerman et al, 2008; Gascoigne and Taylor, 2008;
Wilson et al, 2008). Many studies have focused on identifying
a molecular basis for the origins of observed heterogeneity
(Snijder et al, 2009; Spencer et al, 2009). However, regardless
of its origins, there are many intriguing questions regarding
whether heterogeneity contains biological information. Is
heterogeneity a reproducible property of cellular populations?
At what resolution should heterogeneity be examined? Do
different patterns of heterogeneity reﬂect functional differ-
ences among cellular populations? And, does heterogeneity,
observed with different readouts, contain similar information?
We choose cancer as a biological context to investigate
whether information is contained in cellular heterogeneity.
Classically, cancer cells have been shown to exhibit a high
degree of heterogeneity in phenotypes, such as signaling and
drug response (Heppner, 1984; Rubin, 1990; Anderson et al,
2006; Ichim and Wells, 2006; Campbell and Polyak, 2007;
Cohen et al, 2008; Gascoigne and Taylor, 2008). In practice,
this phenotypic heterogeneity is often ignored as ‘noise’ or
viewed as an impediment to understanding the response of
cancer cells to drugs. Determining the response of cancer cell
populations to drug perturbations is an important challenge in
basic and clinical research. Promising results based on population-
averaged methods have come from large-scale proﬁling of
genomes (van ‘t Veer et al, 2002), mRNAs, and miRNAs across
different cancer populations (van ‘t Veer et al, 2002; Lu et al,
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speciﬁc drug-response pathways are known, directed studies
of mutational heterogeneity among cancer populations can
also be effective in searching for signatures of resistance (Choi
et al, 2007; Engelman et al, 2007; Liegl et al, 2008). These
approaches require pooling analytes from many cancer cells,
which obscures information that might be encoded as cellular
heterogeneity within a cancer population. Recent studies have
begun quantifying cellular variability within single cancer
populations after perturbation with drug treatment (Cohen
etal,2008;GascoigneandTaylor,2008;Slacketal,2008;Brock
et al, 2009; Spencer et al, 2009). However, it is unknown what
information can be revealed through characterization of
heterogeneity before treatment, and further, whether such
measures can be reliably related to the drug sensitivities of
cancer populations.
Understanding the relevance—if any—of cellular diversity
to cancer requires quantitative approaches for relating
patterns of heterogeneity to functional outcomes, such as
drug sensitivity. In practice, close examination of any cellular
population will reveal heterogeneity, and it is a challenge to
identify which components of phenotypic variability contain
functionally important information. Developments in high-
content imaging and ﬂow cytometry have enabled the
comparison of heterogeneity across multiple populations and
conditions (Singh et al, 2003; Kiel et al, 2005; Wang et al, 2007;
Kotecha et al, 2008; Slack et al, 2008). Image-based methods
can capture phenotypic heterogeneity arising from the spatial
distribution ofsignaling moleculeswithin individual cellsand,
ultimately, be extended to account for other, higher-order
determinants of in vivo heterogeneity, including spatial
organization and microenvironment within healthy and
diseased tissues.
Earlier,wedevelopedaquantitative,image-basedapproachto
characterize heterogeneity observed within and among cellular
populations, based on patterns of signaling marker colocaliza-
tion (Slack et al, 2008). The heterogeneous responses of drug-
treated cancer populations were characterized as mixtures of
phenotypically distinct subpopulations, each modeled around a
‘stereotyped’ cellular phenotype. Patterns of heterogeneous
responses were shown to be reproducible, and models of
heterogeneity—based on a limited, but nontrivial number of
subpopulations—were shown to be sufﬁcient to distinguish
different classes of drugs based on their mechanism of action.
Here, in complement to our previous study, we investigated
the extent to which patterns of basal signaling heterogeneity,
present within cancer populations before treatment, revealed
information about population-level response to drug perturba-
tion. Inthiscase,we usedprediction of population drugsensitivity
as an objective measure of the degree to which our decomposi-
tion of heterogeneity contained biological information.
Results
Experimental approach for capturing
heterogeneity of basal signaling states
Determining which aspects of heterogeneity contain informa-
tionrequiresacollectionofpopulationswithdiverseoutcomes
for a speciﬁc functional readout. We initiated our studies by
generating a collection of 49 low-passage clonal populations
from the highly metastatic non-small cell lung cancer cell line
H460 (Supplementary Figure 1A) (Ichim and Wells, 2006).
Consistent with earlier studies of clonal populations, varia-
bility among the H460 clones was observed for functional
readoutssuchasgrowthrate,totalcellcount,localcelldensity,
and cell morphology (Supplementary Figure 2) (Heppner,
1984; Carney et al, 1985). This collection of cancer popula-
tions, with similar genetics and cell type, therefore, provided
an ideal test bed for our investigations.
Which cellular readouts should be selected to capture
heterogeneity? One approach is to select speciﬁc biomarkers
that target conjectured or known links between cellular
mechanism and functional outcome (Snijder et al, 2009).
However, the focus of our study was to identify signatures of
heterogeneity thatmaybeinformativeinthecontext ofdiverse
cancer types. Therefore, we took an alternative approach
and selected combinations of general signaling readouts to
capture the heterogeneity of cellular populations in ‘basal’
(untreated) conditions. Four multiplexed immunoﬂuorescent
marker sets (MS) were chosen and studied independently
(Supplementary Table 1; MS1: DNA/pSTAT3/pPTEN; MS2:
DNA/pERK/pP38; MS3: DNA/E-cadherin/pGSK3-b/b-cate-
nin; and MS4: DNA/pAkt/H3K9-Ac). These biomarkers,
selected to monitor the activity levels of key signal transduc-
tion components associated with diverse areas of cancer
biology (Bremnes et al, 2002; Pandolﬁ, 2004; Zhou et al, 2004;
Haura et al, 2005; Normanno et al, 2006; Stewart et al, 2006;
Barre et al, 2007; Rocques et al, 2007) enabled us to obtain a
snapshot of the ensemble of cellular signaling states present
within our clonal cancer populations.
Identiﬁcation of common cellular signaling
stereotypes
Awiderangeofsignalingphenotypeswasobservedwithinand
across untreated clonal populations based on immunoﬂuor-
escent microscopy images of MS1. Although some clones
Figure 1 Non-small cell lung cancer H460 clones exhibit a high degree of phenotypic heterogeneity. (A) (Top) Cellular heterogeneity can be characterized as a
mixture of phenotypically distinct subpopulations using a Gaussian mixture model (GMM). Shown is the result of computing a ‘reference’ GMM of ﬁve subpopulations.
Points in GMM scatter plots correspond to individual cells, visualized through feature representation and PCA reduction to two dimensions. Colored ellipses represent
covariance 1 s.d. from the mean for each Gaussian cluster (see Supplementary information); cells in this (and all subsequent) scatter plot are colored by the
subpopulation of maximum probability. (Bottom) Images of four representative cells from each computed subpopulation are shown. (B) Clones display phenotypically
diverse signaling states as measured by activation and colocalization patterns of pSTAT3 and pPTEN immunostaining. Although some clones are phenotypically similar
to the parent (e.g. clone 65), others are dramatically dissimilar to the parent (e.g. clone 100). (C)Heterogeneity observed ineachclonal population is summarized with a
subpopulation proﬁle: a vector estimating the proportion of cells in each subpopulation. (D) Cell populations with similar overall distributions of marker intensities may
havedramaticallydifferentproportionsofsubpopulations.Stackedhistogramsofsubpopulationintensitiesareshownfortheparentandtwoclones.Colorscorrespondto
subpopulations identiﬁed in (A). Black outlines correspond to overall histogram; vertical lines indicate population medians. Pseudocolors for images in (A) are speciﬁed
above the scatter plots. Pseudocolors for images in (B) are: DNA-blue, pSTAT3-green, pPTEN-red. Scale bars: 20mm. MS1 refers to marker set 1.
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other clones appeared quite different (Figure 1B; Supplemen-
tary Figure 1B). In addition, within each clone we observed
cells with diverse signaling patterns as deﬁned by marker
intensity and colocalization (Supplementary Figures 1C and D).
However, closer inspection of all 50 cancer populations
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number of signaling ‘stereotypes’; that is, each stereotype was
present, to varying degrees of proportion, within all clones
(Supplementary Figures 1B–D and 3). These observations
suggested that each clonal population could be characterized
as a mixture of a small number of common signaling
stereotypes.
Tocapturecommon signaling stereotypesamong theclones,
we applied an earlier developed approach for approximating
cellular distributions as mixtures of subpopulations, which is
unbiased by prior knowledge of cell- or marker-speciﬁc
phenotypes (Supplementary information) (Slack et al, 2008).
In summary, we analyzed each MS independently as follows.
We applied automated cell segmentation to our image data
(Loo et al, 2007), extracted cellular features from ratios of
marker intensities at every pixel within a cellular region, and
identiﬁed a small number (Bp10) of ‘maximally informative’
signaling features by principal component analysis (PCA)
(Supplementary information) (Turk and Pentland, 1991; Slack
et al, 2008). These PCA-based features were used in all
subsequent analysis (though only the ﬁrst two dimensions,
PC1 and PC2, are used for visualization).
Approximately 4000 cells were analyzed per MS and per
clone(B200000cellsperMS).ForeachMS,a‘reference’setof
cells was generated by randomly subsampling B10% of cells
from all the 50 H460 populations. Finally, each reference set
was represented as a mixture of subpopulations, modeled as
Gaussian distributions with means centered on distinct,
‘stereotyped’ signaling states (Figure 1A, top panel; Supple-
mentary information). (Other choices of distributions for
approximating local, high-density regions of cellular feature
space, such as skew t-distributions (Pyne et al, 2009), could be
made in future studies. Such choices may provide better
approximations when the distributions are not normally
distributed or may better model speciﬁc biological pheno-
types.)Wethen usedour mixturemodeltoassign toeachcella
probability of belonging to each subpopulation. These
probabilities were used for all subsequent analysis, though
for visualization purposes cells were assigned to the sub-
population of highest probability (Figure 1A, scatter plot).
The heterogeneity of each cell population was estimated
by using our computed reference subpopulation model (Slack
et al, 2008). In brief, the (posterior) probability of each cell
belonging to the identiﬁed subpopulations was computed
using Bayes’ rule and represented as a probability vector
whose entries summed to one. An expected overall proportion
of each subpopulation was computed by averaging these
probability vectors over the cell population to obtain a
subpopulation proﬁle. Replicates were averaged to obtain a
single ﬁnal proﬁle of subpopulation fractions per condition. In
essence, these proﬁles of probability vectors (p1,y,pk) yielded
a decomposition of each population, D, as a weighted mixture,
DE
P
psDs, of the k reference subpopulation distributions, Ds.
These proﬁles provided interpretable summarizations of
heterogeneity present within the clones, and captured
differences in subpopulation fractions, such as due to
enrichment of cells into different phenotypic states and/or
general population shifts.
To evaluate the optimal number of subpopulations, we
applied two standard model ﬁt criteria: Bayesian information-
theoretical criterion and the Gap statistics. These standard
performance metrics evaluate models by rewarding ﬁt to data,
but penalize over ﬁtting due to increased model complexity.
Our results suggested that cellular heterogeneity among all 50
H460 populations inour four MScould be reasonably modeled
by a low number (3–7) of signaling stereotypes (Supplemen-
tary Figure 4). For convenience, in subsequent analysis we
chose to use reference models of ﬁve subpopulations for all
MS; this choice is in line with the estimates of model ﬁt, and
allowed us to test whether a small number of subpopulations
could capture information contained in cellular heterogeneity.
Examination of representative cells from the ﬁve identiﬁed
subpopulations (chosen near the mean of each Gaussian
distribution) revealed consistent and signiﬁcant differences in
the activation levels of key signaling proteins (Figure 1A,
bottom panel). (We noted that the subpopulations were not
particularly enriched for speciﬁc cell-cycle states; Supplemen-
tary Figure 5.) Importantly, identiﬁcation of these subpopula-
tions revealed dramatic differences in heterogeneity among
clones that were not easily distinguished on the basis of
population-level statistics of average cellular marker expres-
sion alone. For example, clone #65, clone #100, and the parent
have essentially indistinguishable means and relatively
similar distributions of intensities for pSTAT3 and pPTEN
in MS1 (Figure 1B–D). However, the mixture of subpopula-
tions for clones #100, 65 and the parent were distinct
(though #65 appears closer to the parent mixture than #100)
(Figure 1C and D). These small collections of subpopulation
phenotypes provided an intermediate (less complex than
single cell but more informative than population average)
resolution for examining and comparing heterogeneity ob-
served among our H460 clones.
Comparison of heterogeneity across clonal cancer
populations
We next compared heterogeneity observed across our entire
collection of H460 clones. We began by studying cellular hetero-
geneity observed with MS1, and then made use of the other
marker sets (MS2–4) to test the dependence of our ﬁndings on
our initial choices of readouts. Differences in heterogeneity
among the clones could be seen as differences in fractions of
cells in each of the ﬁve subpopulations (Figure 2, thumbnail
images and scatter plots). To assess the variation of signaling
heterogeneity among the clones, we transformed the sub-
population proﬁles of the clones to reﬂect their log-fold
enrichment of subpopulations compared with the parent, and
grouped the proﬁles by hierarchical clustering based on their
Euclidean distances (Supplementary information). Interest-
ingly, clustering of the enrichment proﬁles revealed a
relatively small number of distinct patterns (or ‘signatures’)
of signaling heterogeneity (MS1 is shown in Figure 2; MS1–4
are shown in Supplementary Figure 6). In addition, subpopu-
lation proﬁles from replicates of the same clone were much
more similar to each other on average than replicates of clones
selected from different clusters, indicating that our proposed
measures of heterogeneity were experimentally reproducible
(Supplementary Figure 8). Thus, cell-to-cell variation was
captured by a few signaling stereotypes common to all the
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heterogeneity were observed within our collection of clonal
populations. Our decomposition of observed cell signaling
heterogeneity provided an approach to visualize the diversity
of heterogeneity among our clones, succinctly encapsulate the
apparent complexity of cancer phenotypes, and compare
clones at a resolution greater than provided by population
means.
Classiﬁcation of drug sensitivity from patterns
of signaling heterogeneity
Do patterns of subpopulation mixtures reﬂect functional
differences among the clones? It is known that not all cancer
subpopulations respond equally to drugs (Tang et al, 2007;
Cohen et al, 2008; Gascoigne and Taylor, 2008). Hence, we
wondered whether clones with similar patterns of pre-existing
heterogeneity would have similar drug sensitivities. The H460
cancer populations were given identical 48h treatments of the
chemotherapeutic drugs paclitaxel (10nM) and doxorubicin
(1mM). Cells were then ﬁxed and stained with standard
markers for apoptosis, and an index of relative drug sensitivity
for each clone to the parent was computed based on the
log ratios of remaining nonapoptotic cell counts; negative
(or positive) values indicated greater drug resistance (or sen-
sitivity) than the parent (Supplementary information). We
observed that clones with similar patterns of heterogeneity
tended to have similar drug sensitivities (Supplementary
Figure 3). As most clones had similar sensitivities to paclitaxel
and doxorubicin, we carried our analysis forward using only
paclitaxel. Hierarchical clustering (MS1 is shown in Figure 2,
MS1–4 are shown in Supplementary Figures 6 and 7) and
multidimensional scaling (Figure 3A) (Borg and Groenen,
1997) of subpopulation proﬁles revealed striking separation
of paclitaxel-sensitive from paclitaxel-nonsensitive clones.
(As expected, cells stained without primary antibodies, but
with secondary antibodies plus Hoechst alone, yielded no
separation; Supplementary Figure 9.) Thus, heterogeneity
of cellular signaling states observed in our untreated H460
clones contained information that captured sensitivity to
drug treatment.
To what extent does the separation of drug sensitivities
based on patterns of pre-existing heterogeneity depend on MS
choice? We observed that the nearest neighbors of a clone in
one MS were often close neighbors in the other MS
(Supplementary Figure 10); there were B20 clones whose
three-nearest neighbors in MS1 remained close in MS2 (46-
fold more than expected by chance). Further, the sets of
nearest neighbors of a clone across marker sets tended to have
similaraveragedrugsensitivities,independentof ourchoice of
MS(Figure3B). Conversely, clones ofsimilardrug sensitivities
tended to have similar phenotypes across all marker sets
(Figure 3C; Supplementary Figures 3 and 10). The consistency
of information across signaling markers and clones suggested
the possibility that similar patterns of cellular heterogeneity
were reﬂective of ‘deeper’similarities of underlying regulatory
networks.
How separable are the collections of ‘sensitive’ and
‘resistant’ subpopulation proﬁles? We computed the accuracy
of separating these two classes of proﬁles using a linear
support vector machine (Supplementary information). Our
complete set of H460 clones had separation accuracies
between B70 and 76% for our MS (Figure 4A-I, MS1–4).
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Figure 2 Distinct patterns of signaling heterogeneity can be compared across H460 clones. Shown are results computed using marker set 1 (DNA/pSTAT3/pPTEN);
pseudocolors for the thumbnail images are as in Figure 1B. At the top are the representative GMM scatter plots from eight clones and the parent (P) culture. Below are
thumbnailimages of each clone. Yellow/blue heat map shows enrichment/de-enrichment of subpopulations (rows) for all clones (columns). Proﬁles are computed as the
log ratio of clone subpopulation proportions relative to the parent. Clone clustering is determined by hierarchical clustering (dendrogram at bottom). The dendrogram is
plotted to produce decreasing average sensitivity to paclitaxel (colored squares above the heat map; Supplementary information). Paclitaxel sensitivity is scored relative
to the parent and displayed in red (resistant) and green (sensitive) color scale (gray: paclitaxel-sensitivity scores of clones 33 and 35 are unreliable due to an image-
focus problem.) (Supplementary information). Similar results using marker sets 2–4 are shown in Supplementary Figure 6.
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‘extreme’ sensitivities were much higher (B80–100% for the
10 or 20 most sensitive and resistant clones) (Figure 4A-I,
MS1–4; Supplementary Figure 11A). A repeat experiment
gave similar results. However, as may be expected from
other studies of clones (Chang et al, 2008), we observed
that separation accuracy of our low-passage H460 clones
decreasedovertheperiodofamonth(SupplementaryTable5).
Finally, to assess the predictive value of our model of H460
heterogeneity, we recomputed separation accuracies using a
leave-one-out strategy (Supplementary information).Prediction
accuracies for the complete and ‘extreme’ sets of clones
were similar, though slightly reduced, to the full separation
accuracies (66–73% and 80–90%, respectively) (Supplemen-
tary Figure 12) across MS1–4. Thus, clones with extreme
opposite sensitivities had distinct and separable patterns
of heterogeneity: distinct patterns of heterogeneity reﬂected
functional divergence.
Classiﬁcation of drug sensitivity in diverse cell
populations
We wondered whether the phenotypic diversiﬁcation and
separation of drug sensitivity by cellular heterogeneity would
also hold for a collection of noncancer clone populations. We
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Figure 3 Clones with similar patterns of subpopulation proﬁles have similar drug sensitivities. Clone IDs and relative sensitivities to paclitaxel are as in Figure 2.
(A) Paclitaxel-sensitive clones can be separated from nonsensitive clones based on patterns of subpopulation proﬁles. Multidimensional scaling (MDS) is used to
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similarpaclitaxelsensitivitytendtobephenotypicallysimilar acrossallfourmarkersets.Thumbnailsofclones(columns)labelledin(A)areshownforallfourmarkersets
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noncancerous, immortalized human bronchial epithelial cell
(HBEC) clones (Vaughan et al, 2006) stained with MS1 and
MS4. The HBEC clones showed reduced ranges of overall
heterogeneity and drug sensitivities compared with the H460
cancer clones (Figure 4B), as monitored by our assay, and
showed no signiﬁcant separation, even when tested on the
subset of clones with extreme paclitaxel sensitivities (Figure
4A-II; Supplementary Figure 11B). In addition, separation was
poor even after building an HBEC reference model of
heterogeneity (data not shown). These results were consistent
with the expectation that cancer is associated with increased
phenotypic heterogeneity compared with normal cells (Hepp-
ner, 1984; Rubin, 1990; Campbell and Polyak, 2007; Gascoigne
and Taylor, 2008). Thus, in contrast with the H460 cancer
clones, among these noncancer HBEC clones, heterogeneity
provided no additional information for separating functional
differences, presumably due to greater similarity among
founder cells and/or more tightly regulated ranges of
signaling states.
We next tested whether models of cellular heterogeneity
developed on the H460 clones could reveal information about
the drug sensitivity of cellular populations of diverse cancer
types. We applied our H460 model of heterogeneity to nine cell
linesselectedfromtheNCI-60panel(Shankavarametal,2009)
with extreme GI50 values for paclitaxel (NCI-9—ﬁve sensitive
and four resistant) (Supplementary information). These
selected cell lines were derived from breast, colon, lung,
ovarian, and renal cancers (Supplementary Table 2). Remark-
ably, subpopulation proﬁles for these populations were well
separated by paclitaxel sensitivities using MS4, and to a lesser
degree MS1 (Figures 4A-II and C; Supplementary Figure 11B).
Here, similar separation accuracies could also be obtained
using a reference model of heterogeneity built entirely from
subsampled cells within the NCI-9 cell lines (Supplementary
Figure13).Aswiththeclones,repeatexperimentsgavesimilar
separation accuracies. However, in this case, separation
accuracies remained similar (and high) even after 2 months
of additional time in culture (Supplementary Table 5). As
might be expected, the observed relationship between hetero-
geneity and drug sensitivity was more stable for these well-
established cell lines than for the low-passage clones. These
results suggested that diverse cancer types may share an
overlapping repertoire of signaling states (Jones et al, 2008;
Parsons et al, 2008; Valle et al, 2008), whose heterogeneous
ensembles have similar relationships to function.
To what extent did the identiﬁcation of information
contained in cellular heterogeneity depend on the choices
made in our study? Clearly, not every marker set, feature, or
model parameter will be equally informative. For example,
paclitaxel sensitivity among the H460 and NCI panels could
neither be predicted by a panel of markers including its
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Figure 4 Models of H460 lung cancer heterogeneity can be used to classify sensitivity to paclitaxel for other cancer populations. (A) Accuracies of separating
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either resistant or sensitive classes; ‘Extreme 2N:’ populations only included when in the N-most sensitive or resistant populations. All subpopulations are computed
based on H460 reference model.
zAccuracy not statistically signiﬁcant (P40.05).
wAccuracy not 1 s.d. above the average accuracy over all possible permutations of
resistant/sensitive assignments (Supplementary Figure 11). *The least resistant cell line was not used for SVM analysis to create a balanced (four resistant, four
sensitive) data set (Supplementary information). (B) Noncancerous HBEC clones display less diversity than the panel of H460 clones. (Top panel) HBEC clones show
reducedrangesofdrugsensitivities (bottompanel)anddissimilarityamongphenotypicproﬁlescompared withH460clones.Referencemodelforbottompanelisbuiltby
sampling both HBEC and H460 clones; the number of subpopulations is varied from 3 to 14. Error bars are 90% conﬁdence intervals based on bootstrapping
(Supplementaryinformation).(C)Drugsensitivityamongdiversecancerpopulationscanbeseparatedbysubpopulationproﬁles.TheH460referencemodelwasusedto
compute subpopulation proﬁles for nine adherent cell lines with the most extreme GI50 values for paclitaxel within the NCI-60 panel.
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a panel of ‘neutral’ markers MS6: DNA/GAPDH/Pericentrin
(Figure 4A-I, MS5–6; Supplementary Figures 11A, 12, and 14).
Alternatively, for the sole purpose of developing functional
predictions, it may be possible to identify speciﬁc markers and
features whose population-averaged measurements can pro-
vide accurate classiﬁcation. For example, the average intensity
of b-catenin in MS3 provided exceptional classiﬁcation accu-
racy among all markers (accuracy¼78.72%, Po0.05 for the
complete set of H460 clones). Population-averaged measure-
ments also lend themselves to multiplexed assays, such as
those performed with array-based technology; features based
on population-averaged measurements can be easily com-
bined from parallel assays, thereby allowing greater numbers
of markers to be explored than can be studied at present on
individual cells. However, information may be lost; classiﬁca-
tion of paclitaxel sensitivity based on population-averaged
expression of any three random randomly chosen readouts
from MS1–4 performed on average 5% poorer (or 10% if
b-catenin was dropped) than our heterogeneity proﬁles
based on three readouts. Furthermore, ensemble-averaged
measurements may be predictive of function (e.g. drug
response), yet poorly represent individual cellular behaviors
and lead to inaccurate models of cell function (Ferrell and
Machleder, 1998). Finally, a critical parameter for decom-
posing heterogeneity is the coarseness of the approxima-
tion (Yin et al, 2008; Pyne et al, 2009). In cross-validation
studies, we found that the range of subpopulation numbers
suggested by model ﬁt criteria (i.e. 3–7 subpopulations)
coincided well with the range that provided highest separation
accuracies of the H460 clones by drug sensitivities (Supple-
mentary Figure 15). In future, reﬁnement of model parameters
may be improved by incorporating additional biological
knowledge to determine when subpopulations should be
merged or further split.
Discussion
Cellular heterogeneity has been classically described within
cellular populations, both in the settings of cell culture and
in vivo. Heterogeneity, as an absolute property of a cellular
population and collection of molecular readouts, can be difﬁcult
to interpret. However, relative differences in heterogeneity,
such as may be due to epigenetics, genetics, or environmental
conditions, may be more interpretable, in particular when
tested for correlation with functional differences.
In the context of differences due to pharmacological
perturbations, heterogeneity may be observed before or after
treatment. In earlier work (Slack et al, 2008), the ability to
distinguish mechanistic classes of perturbations based on
heterogeneous cancer cell responses was studied. In contrast,
here we investigated whether patterns of basal signaling
heterogeneity contained information predictive of subsequent
population response to perturbation. We used drug sensitivity
classiﬁcation to provide an objective test of whether our
decomposition of heterogeneity contained biologically relevant
information. (It was not the goal of this study to develop or
optimize predictors for drug sensitivities that outperform other
methods.) We modeled the (quasi-equilibrium) distributions of
cell signaling phenotypes present within populations from
snapshots of large numbers of cells (Chang et al, 2008; Huang
et al, 2009), and found that measures of these distributions
served as informative, predictive readouts of population-level
responses to perturbation. Our approach allowed us to decom-
pose heterogeneous cellular distributions into a small number
of more phenotypically homogenous states (Figure 1), com-
pare and group populations based on their patterns of
heterogeneity (Figure 2), identify a consistent relationship
between heterogeneity and function across multiple sets of
general signaling markers (Figure 3) and, ﬁnally, test whether
a common model of basal signaling heterogeneity could be
used to predict drug sensitivities across different cancer
populations (Figure 4). In general, characterization of the
ensemble of subpopulation mixture may be required to
distinguish functional differences among populations. How-
ever, in certain cases, (de-) enrichment for speciﬁc subpopula-
tions may be sufﬁcient to account for overall functional
differences. For example, in MS1, enrichment for subpopula-
tion pairs (S1, S4) or (S2, S3) separated paclitaxel-sensitive
from -nonsensitive clones (Supplementary Figure 6). Future
studies are required to investigate the deeper molecular states
of speciﬁc subpopulations (Loo et al, 2009a,b) and their
relationship to drug response. We note that in this study,
cellular phenotypes were captured on the basis of the spatial
colocalization patterns of signaling activity readouts from
ﬁxed cells. The physical sorting and subsequent investigation
of our identiﬁed subpopulations remain challenging.
Important questions remain, such as the origins and
evolution of the phenotypic diversiﬁcation, why our decom-
position of heterogeneity predicts drug responsiveness in
our deﬁned culture conditions, and why classiﬁcation is
possible on the basis of a limited number of biomarkers that
were not chosen based on a prior knowledge of the biology of
drug responsiveness, but rather on a general survey of
pathways implicated in cancer. The observed heterogeneity
among the H460 clones could be due to several factors,
including differences in epigenetic states and genetic diversity
that may have been present within the parent population or
evolved within the clones during their short time of establish-
ment. Regardless, we found that a simple description of the
observedheterogeneitycontained functional information.One
possibility for our success using a limited number of
biomarkers may be that our subpopulations reveal ‘deeper’
underlying states that broadly reﬂect signaling in multiple
pathways, and thus may be distinguishable bya small number
of ‘general’ signaling markers. Another possibility is that our
approach has connected the characteristic behaviors of
regulatory networks in two operating regimes: namely,
networks operating within each cancer clone shape the
stochastic distributions of cell signaling states in unchallenged
conditions (Huang et al, 2009) as well as determine an overall
population response to an acute challenge (i.e. drug treat-
ment). It is also interesting to speculate whether patterns of
heterogeneity observed in primary cancer samples can be
interpreted to reveal clinically important information. Impor-
tantly, the answer to this question is independent of whether
proﬁlesof clinical and cellline samples directlysharecommon
signatures. Nevertheless, the potential to study the physio-
logical states of cell populations at a resolution greater than
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cells, is highly compelling and our approach may help to
interpret heterogeneity observed in healthy and diseased
tissues.
Materials and methods
Allcloneswereseededintriplicateonthe samedayontoseven 96-well
plates (each plate contained seven clones and the parent), grown
under identical conditions for 16h, ﬁxed, stained with the four MS,
and imaged at  20 magniﬁcation. Image intensities were scaled for
each plate to normalize parental replicates among all plates.
Subpopulation proﬁles were performed as described earlier (Slack
et al, 2008) (Supplementary information).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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